US research institute to create new campus on the Oxford Science Park

Lawrence J. Ellison Institute for Transformative Medicine, a US research organisation, is to create a new campus to build collaborations across the Oxford life science ecosystem

Leading US-based research organisation, the Lawrence J.Ellison Institute for Transformative Medicine, is significantly expanding its commitment to Oxford by establishing a major presence at The Oxford Science Park (TOSP), one of Europe’s leading locations for science and technology companies.

To facilitate the development of the Ellison Institute’s new Oxford campus, TOSP has agreed to sell a 150-year lease on a 3.5  acre site in the Park. This will connect directly with the adjacent 5.9-acre Littlemore House site that the Ellison Institute acquired in December 2021, creating a major presence in Oxford. The Ellison Institute’s Oxford campus will provide a permanent home to research laboratories, a patient clinic, offices, and collaborative spaces supporting Ellison Institute projects, including the Global Health Security Consortium’s work on pandemic preparedness. The development will enable the Ellison Institute to collaborate extensively with companies and organisations across the Park, as well as the wider Oxford innovation ecosystem. The new location also enables the Ellison Institute to expand its existing partnership with Oxford Nanopore Technologies, one of the major international companies based at the Park.

Rory Maw, CEO of The Oxford Science Park, said, ‘We’re delighted to welcome the Ellison Institute to the Park and look forward to working with the team to help deliver their vision for the new Oxford campus. This commitment will reinforce the ground-breaking research and development already taking place on the Park, delivering benefits and opportunities for our occupiers and the wider Oxford innovation ecosystem.’

 

Dinah Rose QC, President of Magdalen College, said, “Following closely on from our strategic partnership with GIC, the Singapore sovereign wealth fund, this is an exciting next step in the evolution of the Park. We look forward to developing a close long-term relationship with the Ellison Institute and to enhancing further Oxford’s enormous contribution to addressing global health challenges.’

 

‘We look forward to continuing the development of our Oxford presence and partnerships,’ said Dr David Agus, founding director and CEO of the Ellison Institute. ‘These acquisitions give us greater capacity to undertake critical biomedical research as well as the educational initiatives of the Institute in collaboration with Oxford University.

Recent news

Advanced Oxford welcomes new companies

Advanced Oxford welcomes new companies

Six companies join as Early-Stage Company members Advanced Oxford is delighted to welcome six new companies into our membership. Brill Power , ColdQuanta , Learning with Experts , Lightricity, Nucleome Therapeutics and Quantum Dice have joined us in our work to...

read more
Times Higher Education article – female academic founders

Times Higher Education article – female academic founders

Advanced Oxford member and collaborator considers the role of investors in supporting female academic founders Simonetta Manfredi is a professor of equality and diversity management, and the Director for Research, Innovation and Enterprise at Oxford Brookes...

read more
Amano Enzyme establishes new European hub at Milton Park

Amano Enzyme establishes new European hub at Milton Park

The world’s leading manufacturer of speciality enzymes, has established its new Europe, Middle East and Africa (EMEA) hub at Milton Park. Amano Enzymes, the Japanese biotechnology company - which uses its enzymes to boost the flavour, texture, colour, digestion and...

read more
Loading...